Study 175, an unpublished and preliminary comparison of Avandia and Actos by GSK researchers. Study 175 data indicate that Actos lowers blood levels of triglycerides, a cardiovascular risk factor ...

Washington (CNN)-- A Food and Drug Administration committee delivered a split verdict on the diabetes drug Avandia on Wednesday, with most members voting to leave it on the market but recommending ...

An US Food and Drug Administration panel of medical advisors is expected to begin a two-day meeting today to revisit the six-year-old debate regarding the safety of GSK's diabetes drug ...

The drugmaker’s own evidence shows that it could have added a warning to Avandia’s label regarding the drug’s cardiovascular health risks in 2005 but never made a formal application to make a label ...

Still, your choice of diabetes drugs does have implications for heart health, since recent research suggests that one of those drugs—rosiglitazone (Avandia)—actually increases the risk of a ...

Next month, the Obama-era US Food and Drug Administration (FDA) will confront what is likely to be the most defining moment in its short history. In a public meeting scheduled for mid-July, a ...

Most residents near a scenic fishing village in southwestern England were told their tap water is safe to drink again after a parasite sickened more than 45 people ...

The practice of selectively publishing only positive findings and hiding negative results has occurred with other blockbluster drugs, including Vioxx (a painkiller), Avandia (an anti-diabetes drug), ...

According to Avandia.com, "Avandia can cause or worsen heart failure". There has been growing concern regarding Avandia, which was released to the market 10 years ago for people with type 2 diabetes.

Examples of these medications include: Diabeta (glyburide) Avandia (rosiglitazone) Invokana (canagliflozin) Januvia (sitagliptin) However, other options are available, including some injectable ...

Congressional Hearing on Avandia The hearing, along with the recent Senate report, is seen as a building up of pressure on the FDA to take some action on Avandia at the forthcoming advisory ...